574729-44-5 Usage
Uses
Used in Pharmaceutical Industry:
3-tert-Butoxycarbonylamino-2-(3,4-dichloro-phenyl)-propionic acid is used as an analgesic for its ability to relieve pain, making it suitable for treating various types of discomfort.
3-tert-Butoxycarbonylamino-2-(3,4-dichloro-phenyl)-propionic acid is used as an anti-inflammatory agent to reduce inflammation, which is beneficial in managing conditions such as arthritis and menstrual cramps.
3-tert-Butoxycarbonylamino-2-(3,4-dichloro-phenyl)-propionic acid is used as an antipyretic to lower fever, helping to regulate body temperature in cases of elevated heat due to illness or other causes.
3-tert-Butoxycarbonylamino-2-(3,4-dichloro-phenyl)-propionic acid's mechanism of action involves inhibiting the production of prostaglandins, which are chemicals responsible for pain and inflammation in the body. This makes 3-tert-Butoxycarbonylamino-2-(3,4-dichloro-phenyl)-propionic acid an effective treatment option for a range of conditions that involve these symptoms.
Check Digit Verification of cas no
The CAS Registry Mumber 574729-44-5 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 5,7,4,7,2 and 9 respectively; the second part has 2 digits, 4 and 4 respectively.
Calculate Digit Verification of CAS Registry Number 574729-44:
(8*5)+(7*7)+(6*4)+(5*7)+(4*2)+(3*9)+(2*4)+(1*4)=195
195 % 10 = 5
So 574729-44-5 is a valid CAS Registry Number.
574729-44-5Relevant academic research and scientific papers
Discovery of pyrrolopyrimidine inhibitors of Akt
Blake, James F.,Kallan, Nicholas C.,Xiao, Dengming,Xu, Rui,Bencsik, Josef R.,Skelton, Nicholas J.,Spencer, Keith L.,Mitchell, Ian S.,Woessner, Richard D.,Gloor, Susan L.,Risom, Tyler,Gross, Stefan D.,Martinson, Matthew,Morales, Tony H.,Vigers, Guy P.A.,Brandhuber, Barbara J.
scheme or table, p. 5607 - 5612 (2010/11/17)
The discovery and optimization of a series of pyrrolopyrimidine based protein kinase B (Pkb/Akt) inhibitors discovered via HTS and structure based drug design is reported. The compounds demonstrate potent inhibition of all three Akt isoforms and knockdown of phospho-PRAS40 levels in LNCaP cells and tumor xenografts.
Indazole compounds useful as protein kinase inhibitors
-
, (2008/06/13)
The present invention provides compounds of formula I: or a pharmaceutically acceptable derivative thereof, wherein R1, R2, V1, V2, and V3 are as described in the specification. These compounds are inhibitors of protein kinase, particularly inhibitors of AKT, PKA, PDK1, p70S6K, or ROCK kinase, mammalian protein kinases involved in proliferative and neurodegenerative disorders. The invention also provides pharmaceutical compositions comprising the compounds of the invention and methods of utilizing those compositions in the treatment of various disorders.
